The FDA has approved the world’s first 3D printed drug for the treatment of epilepsy. The new drug, Spritam, was developed by Aprecia Pharmaceuticals to control seizures brought on by epilepsy. The 3D technology allows Spritam (levetiracetam) to have higher manufacturing precision thus accommodating a higher dose almost upto 1000 mg in each tablet. As each drug will be completely uniform, it also means doses are more consistent.

Although the FDA has previously approved 3D-printed medical devices, this is the first time a 3D-printed product has been approved for use inside the human body.

Spritam is expected to be available in the first quarter of 2016.